Technology | April 15, 2014

Automated breast density measurement technology adds dimension to analysis beyond volume alone


April 15, 2014 — VuComp Inc. announced it has released an updated version of its M-Vu Breast Density technology. The new M-Vu Breast Density 2.0 adds a critical dimension to the analysis of dense breast tissue. The VuComp density category, analogous to the BI-RADS breast density composition category, is now correlated to not only the amount, but also the distribution – the actual dispersion – of fibroglandular tissue.

M-Vu Breast Density automatically and rapidly assesses breast density and provides consistent and accurate measurements. The tool evaluates mammograms by analyzing the structure, texture and dispersion of the tissue, rather than simply estimating total fibroglandular volume. To ensure product effectiveness, the findings of a panel of 13 expert radiologists were used to calibrate the VuComp density categories to the American College of Radiology’s (ACR) Breast Imaging Reporting and Data System (BI-RADS) standard. The M-Vu algorithms quantify areas with a dense appearance that could hide cancer, and convert them to categories corresponding to the recently updated standard. This exclusive approach using appearance-based texture and dispersion analysis provides useful adjunctive information. M-Vu Breast Density is the only commercially available, U.S. Food and Drug Administration (FDA) -cleared system that employs this scientific methodology.

Clinical studies have shown that dense breasts can hide a cancerous lesion by reducing the ability to visualize fine structures and details that could indicate a malignant abnormality, making breast cancer detection in a mammogram more difficult. Patients with dense breast tissue may be recommended for additional screening exams. Legislation has passed in 16 states requiring physicians to notify patients if their breast density is in one of the two higher categories.

“VuComp understands that breast density measurement is deeper than just an analysis of volume,” said Jim Pike, president of VuComp. “We are dedicated to continual improvements in the science of automated density and believe that radiologists will recognize the clinical utility of this tool to be even more useful to their practice than before. We are very pleased that all existing M-Vu Breast Density users will have this important product enhancement available immediately.”

For more information: www.vucomp.com


Related Content

News | Mammography

April 29, 2025 — iCAD, a global provider of clinically proven AI-powered cancer detection solutions, has announced a ...

Time April 29, 2025
arrow
News | Mammography

April 24, 2025 — GE HealthCare will feature its latest advancements in diagnostic accuracy and patient-centered breast ...

Time April 24, 2025
arrow
News | Artificial Intelligence

March 10, 2025 — Lunit, a provider of AI-powered solutions for cancer diagnostics and therapeutics, has published a ...

Time March 10, 2025
arrow
News | Artificial Intelligence

Feb. 19, 2025 — SimonMed Imaging and HeartLung Technologies have signed a strategic partnership to offer HeartLung's AI ...

Time March 04, 2025
arrow
News | Ultrasound Imaging

Jan. 28, 2025 — GE HealthCare recently announced it has received 510(k) clearance from the United States Food and Drug ...

Time January 29, 2025
arrow
News | Breast Imaging

Jan. 8, 2025 — ScreenPoint Medical has acquiredf Biomediq A/S, a research-based company focused on the research ...

Time January 10, 2025
arrow
News | Breast Imaging

Dec.11, 2024 — iCAD, Inc., a provider of clinically proven AI-powered cancer detection solutions, recently announced ...

Time December 18, 2024
arrow
News | Mammography

Dec. 5, 2024 — At RSNA 2024, Lunit and Volpara Health announced their unified vision, focusing on a comprehensive ...

Time December 05, 2024
arrow
News | Mammography

Nov. 26, 2024 — GE HealthCare has introduced the Pristina Via* mammography system designed to enhance the screening ...

Time December 02, 2024
arrow
News | Artificial Intelligence

Dec. 2, 2024 — Lunit recently unveiled follow-up findings from the ScreenTrustCAD trial. This study, conducted at Capio ...

Time December 02, 2024
arrow
Subscribe Now